Want to see JP:7679 full AI Analyst Report?
Top Page
Yakuodo Holdings Co., Ltd.
(7679)
Select Model
Select Model
Rating:57Neutral
Price Target:
¥1,680.00
▼(-22.47% Downside)
Action:Reiterated
Date:04/07/26
The score is held back primarily by weakening cash generation (volatile and negative free cash flow in 2026) and increased leverage from the 2026 debt step-up, along with a technically weak price trend (below key moving averages and negative MACD). These risks are partially offset by steady revenue growth and a reasonable valuation (P/E 12.36) with a modest dividend yield.
Positive Factors
Consistent revenue growth
Sustained top-line expansion reflects steady consumer demand for pharmacy and front‑store goods and supports durable sales visibility. Over 2–6 months this underpins store-level cash flows, purchasing scale and merchandising leverage that bolster operational resilience.
Negative Factors
Volatile and negative free cash flow
Deeply negative and volatile FCF reduces internal funding for capex, store refreshes and working capital, forcing reliance on external financing. Over the coming months this limits strategic flexibility and raises refinancing and liquidity risk if cash conversion doesn't improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Sustained top-line expansion reflects steady consumer demand for pharmacy and front‑store goods and supports durable sales visibility. Over 2–6 months this underpins store-level cash flows, purchasing scale and merchandising leverage that bolster operational resilience.
Read all positive factors
Yakuodo Holdings Co., Ltd. (7679) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥32.04B
Dividend Yield1.29%
Average Volume (3M)32.44K
Price to Earnings (P/E)8.2
Beta (1Y)0.49
Revenue Growth7.80%
EPS Growth-5.42%
CountryJP
Employees978
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)227.00
Shares Outstanding19,740,220
10 Day Avg. Volume22,110
30 Day Avg. Volume32,443
Financial Highlights & Ratios
PEG Ratio-1.88
Price to Book (P/B)1.01
Price to Sales (P/S)0.25
P/FCF Ratio-4.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yakuodo Holdings Co., Ltd. Business Overview & Revenue Model
Company Description
YAKUODO HOLDINGS Co., Ltd. primarily oversees the operation of drugstores throughout Japan via its various subsidiary entities. This enterprise, established in 1978, manages a total of 358 retail locations and is officially headquartered in Moriok...
How the Company Makes Money
The company makes money primarily through retail sales generated at its drugstore locations. Key revenue streams typically include: (1) prescription dispensing, where revenue is earned from filling prescriptions (including dispensing-related fees)...
Yakuodo Holdings Co., Ltd. Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
62
Positive
Cash Flow
44
Neutral
| Breakdown | TTM | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 | Feb 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 157.99B | 163.81B | 151.96B | 142.24B | 128.79B | 120.31B |
| Gross Profit | 31.05B | 31.71B | 29.66B | 27.86B | 25.45B | 24.65B |
| EBITDA | 9.20B | 8.97B | 8.71B | 8.16B | 7.56B | 6.66B |
| Net Income | 4.44B | 4.03B | 4.28B | 3.83B | 3.24B | 2.96B |
Balance Sheet | ||||||
| Total Assets | 88.88B | 103.17B | 80.26B | 71.07B | 68.01B | 62.59B |
| Cash, Cash Equivalents and Short-Term Investments | 6.97B | 10.01B | 7.17B | 4.95B | 5.28B | 4.25B |
| Total Debt | 15.41B | 34.60B | 18.19B | 13.60B | 15.75B | 15.61B |
| Total Liabilities | 50.15B | 62.94B | 43.19B | 37.75B | 38.06B | 35.05B |
| Stockholders Equity | 38.73B | 40.23B | 37.06B | 33.31B | 29.94B | 27.53B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -8.28B | 569.00M | 3.58B | 2.76B | -2.33B |
| Operating Cash Flow | 0.00 | 3.29B | 4.49B | 5.63B | 6.41B | 3.69B |
| Investing Cash Flow | 0.00 | -12.84B | -4.57B | -2.27B | -4.11B | -6.63B |
| Financing Cash Flow | 0.00 | 12.40B | 2.30B | -3.69B | -1.27B | -1.95B |
Yakuodo Holdings Co., Ltd. Technical Analysis
Negative
2167.00
Price Trends
1724.58
Negative
1855.50
Negative
1990.77
Negative
Market Momentum
-29.54
Positive
36.43
Neutral
3.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7679, the sentiment is Negative. The current price of 2167 is above the 20-day moving average (MA) of 1657.75, above the 50-day MA of 1724.58, and above the 200-day MA of 1990.77, indicating a bearish trend. The MACD of -29.54 indicates Positive momentum. The RSI at 36.43 is Neutral, neither overbought nor oversold. The STOCH value of 3.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7679.
Yakuodo Holdings Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥445.13B | 14.20 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥337.81B | 18.58 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥582.77B | 12.81 | 15.71% | 0.96% | 15.07% | 72.98% | |
62 Neutral | ¥899.37B | 14.48 | ― | 1.72% | ― | ― | |
60 Neutral | ¥490.73B | 15.77 | ― | 0.93% | 6.74% | 6.60% | |
57 Neutral | ¥32.04B | 8.18 | ― | 1.29% | 7.80% | -5.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7679
Yakuodo Holdings Co., Ltd.
1,688.00
-596.62
-26.11%
JP:9989
Sundrug Co
3,833.00
-520.08
-11.95%
JP:7649
Sugi Holdings Co
3,186.00
-86.68
-2.65%
JP:3391
TSURUHA Holdings
2,093.00
-102.11
-4.65%
JP:3349
COSMOS Pharmaceutical Corporation
6,274.00
-2,787.71
-30.76%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,640.00
31.01
0.86%
Yakuodo Holdings Co., Ltd. Corporate Events
Yakuodo Posts Double-Digit Sales Growth and Expands Store Network in May 2026
Jun 5, 2026
Yakuodo Holdings reported strong momentum for the fiscal year ending February 28, 2027, with net sales at all stores rising more than 11% year on year in March through May, supported by increases in both customer numbers and average spending. Exis...
Yakuodo Holdings Revamps Top Management in Generational Leadership Shift
May 22, 2026
YAKUODO HOLDINGS CO., LTD. has implemented a leadership transition, appointing Managing Director Takahito Saigo as Representative Director and President, while long-serving leaders Tatsuhiro Saigo and Kiyoko Saigo step down from representative rol...
Yakuodo Posts Strong April Sales Growth on Higher Traffic and Spending
May 7, 2026
Yakuodo Holdings reported robust April 2026 performance, with all-store net sales rising 12.5% year-on-year and existing-store sales up 6.3%. The gains were driven by both higher customer numbers and increased average spending, as existing-store c...
Yakuodo Holdings Moves to Strengthen Board Governance With Articles of Incorporation Change
Apr 20, 2026
Yakuodo Holdings has proposed a change to its Articles of Incorporation that would alter how its Board of Directors is convened and chaired, shifting this authority from the Representative Director and President to a director pre-designated by the...
Yakuodo Starts New Fiscal Year With Strong March Sales and Store Expansion
Apr 6, 2026
Yakuodo Holdings reported a solid start to the fiscal year ending February 28, 2027, with March net sales at all stores rising 10.3% year on year, driven by a 9.4% increase in customer numbers and a modest 0.9% gain in average spend. Existing stor...
Yakuodo Holdings Lifts Sales and Dividend but Faces Margin Pressure
Apr 6, 2026
Yakuodo Holdings reported consolidated net sales of ¥163.8 billion for the fiscal year ended February 28, 2026, up 7.8% year on year, while operating profit slipped 3.6% to ¥5.29 billion and profit attributable to owners of parent declin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.